Baxter International Inc. (BAX)
$
19.16
-3.26 (-17.01%)
Key metrics
Financial statements
Free cash flow per share
0.6491
Market cap
11.7 Billion
Price to sales ratio
1.0742
Debt to equity
1.3286
Current ratio
2.2964
Income quality
5.7955
Average inventory
2.3 Billion
ROE
-0.0212
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Baxter International Inc., through its subsidiaries, has developed a comprehensive portfolio of healthcare products that are distributed globally. The company reported an income before tax of -$289,000,000.00 showcasing its pre-tax profitability. Additionally, the company incurred an interest expense of $408,000,000.00 reflecting its debt servicing obligations. The income before tax ratio is -0.03 illustrating the pre-tax margin effectively. Among its offerings, Baxter provides a range of dialysis therapies, including peritoneal dialysis and hemodialysis, along with intravenous therapies, infusion pumps, and pharmacy compounding services. The EBITDA is $1,116,000,000.00 a key indicator of the company's operational profitability, which underscores its ability to generate earnings before interest, taxes, depreciation, and amortization. The company's stock is identified with the symbol 'BAX' in the market, reflecting its presence in various healthcare sectors. In addition to the core healthcare products, Baxter also supplies connected care solutions and patient monitoring technologies that aid in diagnosing and managing multiple health conditions. The stock is affordable at $23.02 suitable for budget-conscious investors looking for stable options. With a high average trading volume of 7,092,220.00 the stock indicates robust liquidity, attracting diverse investors. Baxter boasts a mid-range market capitalization of $9,840,979,529.00 demonstrating that the company is a steady performer in the healthcare landscape. It is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape with its innovative solutions. Furthermore, it belongs to the Healthcare sector, driving innovation and growth across its service offerings. Thus, Baxter International Inc. not only provides essential healthcare products and services but also positions itself as an attractive investment opportunity with solid foundational metrics.
Is Baxter International Inc. (BAX) a good investment?
Investing in Baxter International Inc. (BAX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Baxter International Inc. (BAX)'s stock forecast?
Analysts predict Baxter International Inc. stock to fluctuate between $18.42 (low) and $37.74 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Baxter International Inc.'s market capitalization?
As of 2025-10-30, Baxter International Inc.'s market cap is $9,840,979,529, based on 513,621,061 outstanding shares.
How does Baxter International Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Baxter International Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Baxter International Inc. pay dividends?
Baxter International Inc. pays dividends. The current dividend yield is 2.75%, with a payout of $0.17 per share.
How can I buy Baxter International Inc. (BAX) stock?
To buy Baxter International Inc. (BAX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for BAX. Place an order (Market, Limit, etc.).
What is the best time to invest in Baxter International Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Baxter International Inc. stock ever split?
Baxter International Inc.'s last stock split was 1841:1000 on 2015-07-01.
How did Baxter International Inc. perform in the last earnings report?
Revenue: $10,636,000,000 | EPS: -$1.27 | Growth: -124.19%.
Where can I find Baxter International Inc.'s investor relations reports?
Visit https://www.baxter.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Baxter International Inc.?
You can explore historical data from here
What is the all-time high and low for Baxter International Inc. stock?
All-time high: $89.70 (2022-02-09) | All-time low: $18.42 (2025-10-30).
What are the key trends affecting Baxter International Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
NEW YORK , Oct. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025.
globenewswire.com
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Baxter International, Inc. (NYSE:BAX), Spirit Aviation Holdings, Inc. (OTCMKTS:FLYYQ), and Molina Healthcare, Inc. (NYSE: MOH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
fool.com
Its third-quarter performance didn't impress market players. Although net sales rose year over year, adjusted profitability declined at a double-digit percentage rate.
globenewswire.com
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX).
zacks.com
Baxter's Q3 earnings top forecasts, but sales lag and 2025 EPS guidance slips; shares fall despite strength in Pharma and Advanced Surgery.
zacks.com
While the top- and bottom-line numbers for Baxter (BAX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
globenewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
seekingalpha.com
Baxter International Inc. ( BAX ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Kevin Moran Andrew Hider - CEO, President & Director Joel Grade - Executive VP & CFO Conference Call Participants Robert Marcus - JPMorgan Chase & Co, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Travis Steed - BofA Securities, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Joanne Wuensch - Citigroup Inc., Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Matthew Taylor - Jefferies LLC, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material.
zacks.com
Baxter International (BAX) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.8 per share a year ago.
prnewswire.com
NEW YORK , Oct. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX). Shareholders who purchased shares of BAX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
See all news
